Medical/Pharmaceuticals
So-Young Announces Board Change
BEIJING, Oct. 12, 2023 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that Mr.Min Yu, Mr. Xuejian ...
2023-10-12 18:00
3324
MicuRx announces poster presentation and participation in ID Week 2023 Conference
FOSTER CITY, Calif., Oct. 11, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, announces that a poster on our preclinical product, MRX-6038, will be p...
2023-10-11 23:33
1744
SINGAPORE AND JAPAN CLINICIAN-SCIENTISTS COLLABORATE ON GROUNDBREAKING TELESURGERY TRIAL SPANNING OVER 5,000KM
This preclinical trial surgery involves clinician-scientists in NUS Medicine and theNational University Hospital in partnership with Fujita Health University SINGAPORE, Oct. 11, 2023 /PRNewswire/ -- Singapore's National University Hospital (NUH) and the Yong Loo Lin School of Medicine at theNatio...
2023-10-11 22:13
2637
Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
SUZHOU, China, Oct. 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional appr...
2023-10-11 17:20
1623
TaiGen Enters Exclusive License Agreement with YSP
TAIPEI, Oct. 10, 2023 /PRNewswire/ -- TaiGen Biopharmaceuticals Holdings Ltd. ("TaiGen") announces that TaiGen Biotechnology, a subsidiary company of TaiGen, have signed an exclusive licensing agreement with Y.S.P. Industries (M) Sdn. Bhd. to develop and commercialize TaiGen's new drug inMalaysia...
2023-10-11 11:24
1657
GC Biopharma Shares its Successful HR System Transformation at SAP Success Connect 2023
YONGIN, South Korea, Oct. 10, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that it has presented the successful adoption of SAP SuccessFactor Work Zone, which is a cloud-based HR solution by SAP, at the SAP Success Connect 2023 held onOctober 3rd in Las Vegas. SAP Success Connect is...
2023-10-11 08:49
1626
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached - Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039 ROCKVILLE, ...
2023-10-10 20:00
1437
GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
SHANGHAI, Oct. 10, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first subject was dosed in a phase Ib/II trial of GFH009 (a highly selective CDK9 inhibitor) treating relapsed/r...
2023-10-10 19:00
1486
CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region
SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in theMiddle East andNorth Africa (MENA) region. "We are thrilled to partner with Hi...
2023-10-10 12:00
1620
Dr. Ming H. Wu, Former Senior Vice President of Engineering at Edwards Lifesciences, Joins Medeologix as Board Member and Advisor
NEW TAIPEI CITY, Taiwan, Oct. 9, 2023 /PRNewswire/ -- Medeologix, a global
medical device contract development and manufacturing company known for its
one-stop shop service with engineering excellence, is pleased to announce that
Dr.Ming H. Wu has joined as a board member and advisor.
2023-10-09 23:00
1658
TransThera announces two oral presentations of tinengotinib clinical data at 2023 ESMO and SABCS annual meetings
NANJING, China, Oct. 9, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announces to deliver two oral presentations of tinengotinib clinical data in cholangiocarcinoma (CCA) at...
2023-10-09 21:00
1574
bioSeedin Biopharma Developer Innovation Conference Held to Accelerate Global Pharmaceutical Innovation and Collaboration
BOSTON, Oct. 9, 2023 /PRNewswire/ -- Recently, the fifth Biopharma Developer Innovation Conference (BDIC) & 2023 bioSeedin Annual Meeting was successfully held inShanghai, China. This conference was hosted by bioSeedin and co-organized by ACROBiosystems (SZ.301080) to promote technical exchanges ...
2023-10-09 20:00
1572
Kexing Biopharm Holds China-MENA & South Asia Pharmaceutical Cooperation High-end Forum, Aiming at Foreign Emerging Markets
SHENZHEN, China, Oct. 9, 2023 /PRNewswire/ -- The 2023 China-MENA & South Asia Pharmaceutical Cooperation High-end Forum and Kexing Biopharm's Series of Globalization Activities were successfully held recently. MENA and South Asia are recognized as pivotal regions for Kexing Biopharm's overseas ...
2023-10-09 19:09
1751
AACR OVARIAN CANCER CONFERENCE PRESENTATION
HIGHLIGHTS * Data from preclinical studies in ovarian cancer presented at premier international conference inBoston, USA. * Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade ser...
2023-10-09 15:18
1372
CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
* LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS * LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally BEIJING and BURLINGTON, Mass. ,Oct. 8, 2023 /PRNewswire/ -- CANbridge Pha...
2023-10-09 08:00
1543
FDA Grants Orphan Drug Designation to GC Biopharma's Drug Candidate for Thrombotic Thrombocytopenic Purpura
YONGIN, South Korea, Oct. 5, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that GC1126A, its drug candidate for Thrombotic Thrombocytopenic Purpura (TTP), received an Orphan Drug Designation onSeptember 27 from the U.S. Food and Drug Administration (FDA). When designated as an orphan...
2023-10-06 08:12
2428
STARmed America Launches, Pioneering Thermal Ablation Innovations in North America
LOS ANGELES, Oct. 5, 2023 /PRNewswire/ -- STARmed Co., Ltd
2023-10-05 20:00
1858
LOTTE BIOLOGICS Announces Land Purchase Agreement with Incheon Free Economic Zone Authority, Establishing New Foothold in Songdo
* Construction of a Bio Plant with a total production capacity of 360 kL at Songdo's Block KI20, Zone 11 by 2030 * Aims to secure capabilities of an international standard and expand client base by making the Bio Plant a key hub SEOUL, South Korea, Oct. 4, 2023 /PRNewswire/ -- LOTTE BIOLOGICS...
2023-10-04 18:14
1594
First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial
SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first ...
2023-10-03 20:58
1976
Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study
- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after CBL-514 treatment. - Compared with placebo, an average of 312.1mL of subcutaneous fat was reduced in...
2023-10-02 21:00
1270
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6217
